Genopole and Ambassador of France to the USA, Mr. Gérard Araud, @ BIO 2018

With 18,000+ attendees, we understand that Guinness World Records were set at BIO-2018, for Largest Partnering Event with nearly 47,000 One-on-One meetings that involved more than 7,900 delegates from 3,900 companies. It was also a very busy BIO this year for Genopole, with lots of circulation at our stand that was well in evidence on France’s booth, a presentation of our cluster at the Global Innovation Hub, a series of One-on-One partnering meetings, as well as a number of meetings with representatives of research parks and bioclusters from the US, China, Korea, Canada, Brazil and other European countries. It is noteworthy mentioning that the number of talks, panels, and presentations on gene and cell therapy as well as on precision medicine are now much in evidence at BIO, and occupying increased space in the program from one year to another.
With the “gene” as a prefix in its name, one can only measure our founders’ vision who 20 years ago this year gave life to Genopole.

Genopole was also a Biotechnology Circle Sponsor (as well as a member of the Program Expert Advisory Board) of the 2nd Boston-Paris Biotechnology Summit, where speakers and panels explored the US and global roadmaps “From the Promise of Raising Capital to the Reality of Clinical Trials”.
The CEO of YposKesi, Alain Lamproye, also made a presentation at the Summit on Genopole’s CDMO that produces gene therapy clinical lots. YposKesi closed a 121m-euro financing in late 2016 by AFM-Téléthon and France’s Banque Publique d’Investissement to triple its current facilities to over 13,000 sq.m and expand production lines to include cell therapy clinical lots. It is in major industry events like BIO that one can appreciate the value and strength of our constituents.